文献速递肝病

格卡瑞韦/哌仑他韦治疗基因3型丙型肝炎病毒感染合并肝硬化及/或既往治疗经历患者:一项部分随机化的3期临床试验

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
PubMed 文献 · Hepatology · 2018-01-04

SURVEYOR-II第3部分是一项部分随机、开放标签、多中心3期研究,纳入131例基因3型丙型肝炎病毒感染患者。无肝硬化经治患者随机接受格卡瑞韦/哌仑他韦12周或16周,肝硬化患者分别接受12周(初治)或16周(经治)。各亚组SVR12率为91%至98%,方案耐受性良好。

要点

  • 无肝硬化经治患者12周与16周格卡瑞韦/哌仑他韦的SVR12率分别为91%和95%。
  • 肝硬化初治患者12周SVR12率为98%,肝硬化经治患者16周SVR12率为96%。
  • 无不良事件导致研究药物停药,无与研究药物相关的严重不良事件。

核心结论

  • 基因3型丙型肝炎病毒感染合并既往治疗经历和/或代偿性肝硬化患者接受格卡瑞韦/哌仑他韦12或16周治疗可获得高SVR12率,且方案耐受性良好。

研究设计与样本

  • SURVEYOR-II第3部分是一项部分随机、开放标签、多中心、3期研究,共纳入并治疗131例患者。
  • 无肝硬化的经治患者按1:1随机接受格卡瑞韦/哌仑他韦(300 mg/120 mg)每日一次治疗12周或16周。
  • 代偿性肝硬化初治患者接受12周治疗,经治患者接受16周治疗。
  • 主要疗效终点为治疗后第12周持续病毒学应答率(SVR12)。

主要发现

  • 无肝硬化经治患者中,12周组SVR12为91%(20/22;95%CI 72-97),16周组为95%(21/22;95%CI 78-99)。
  • 肝硬化初治患者12周组SVR12为98%(39/40;95%CI 87-99)。
  • 肝硬化经治患者16周组SVR12为96%(45/47;95%CI 86-99)。
  • 无不良事件导致研究药物停药,无与研究药物相关的严重不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study assessed the efficacy and safety of ribavirin-free coformulated glecaprevir/pibrentasvir (G/P) in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or compensated cirrhosis, a patient population with limited treatment options. SURVEYOR-II, Part 3 was a partially randomized, open-label, multicenter, phase 3 study. Treatment-experienced (prior interferon or pegylated interferon ± ribavirin or sofosbuvir plus ribavirin ± pegylated interferon therapy) patients without cirrhosis were randomized 1:1 to receive 12 or 16 weeks of G/P (300 mg/120 mg) once daily. Treatment-naive or treatment-experienced patients with compensated cirrhosis were treated with G/P for 12 or 16 weeks, respectively. The primary efficacy endpoint was the percentage of patients with sustained virologic response at posttreatment week 12 (SVR12). Safety was evaluated throughout the study. There were 131 patients enrolled and treated. Among treatment-experienced patients without cirrhosis, SVR12 was achieved by 91% (20/22; 95% confidence interval [CI], 72-97) and 95% (21/22; 95% CI, 78-99) of patients treated with G/P for 12 or 16 weeks, respectively. Among those with cirrhosis, SVR12 was achieved by 98% (39/40; 95% CI, 87-99) of treatment-naive patients treated for 12 weeks and 96% (45/47; 95% CI, 86-99) of patients with prior treatment experience treated for 16 weeks. No adverse events led to discontinuation of study drug, and no serious adverse events were related to study drug. Conclusion: Patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or compensated cirrhosis achieved high SVR12 rates following 12 or 16 weeks of treatment with G/P. The regimen was well tolerated. (Hepatology 2018;67:514-523).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Wyles D, Poordad F, Wang S, et al. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. Hepatology. 2018. PMID: 28926120. doi:10.1002/hep.29541

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。